Relapse-free survival in FIP1L1-PDGFRA–positive MLN-eo after discontinuation of imatinib. (A) Kaplan-Meier estimates for loss of CMR after discontinuation of imatinib in 12 patients with FIP1L1-PDGFRA–positive MLN-eo. (B) Kaplan-Meier estimates for loss of CHR/CMR (n = 33) or loss of CMR only (n = 25) after discontinuation of imatinib in 33 patients with FIP1L1-PDGFRA–positive MLN-eo from this series (n = 12) and an additional 19 cases reported in the literature.